TITLE

Necrotizing Soft Tissue Infections: Improved Outcomes with Modern Care

AUTHOR(S)
Tillou, Areti; St. Hill, Charles R; Brown, Carlos; Velmahos, George
PUB. DATE
October 2004
SOURCE
American Surgeon;Oct2004, Vol. 70 Issue 10, p841
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The outcome of necrotizing soft tissue infections (NSTI) remains unchanged despite advances in care. Reasons cited are changing patterns of causative factors, delays in diagnosis, and inadequate antibiotic coverage and surgical treatment. To document outcomes of NSTI after aggressive management and to identify risk factors of mortality and prolonged hospital stay, we reviewed all our patients with NSTI admitted from January 2000 to January 2002. Causative factors, comorbid conditions, site of NSTI, physiologic parameters, symptoms, diagnostic tests, therapeutic interventions, and outcomes were analyzed. Patients were treated aggressively with antibiotics, ad-mission to ICU, and frequent surgical debridements. Of 46 patients identified, 28 (61%) were admitted in ICU, and eight (17%) died. The patients who died had higher admission white blood cell counts (46 ± 22 vs 22 ± 10 x 10³/mm³, P = 0.01), higher admission pain score (8 ± 1 vs 5 ± 3, P = 0.02), longer intervals from admission to antibiotic administration (16 ± 20 vs 6 ± 12 hours, P = 0.02), and fewer surgical debridements (2.6 ± 1.1 vs 3.6 ± 1.7, P = 0.04). No independent risk factors of mortality or ICU admission were identified. We concluded that severe local pain and a significantly elevated white blood cell count on admission should alert the physician to the presence of severe infection and prompt the initiation of expeditious aggressive treatment.
ACCESSION #
14697705

 

Related Articles

  • Suspected ventilator-associated respiratory infection in severely ill patients: a prospective observational study. Shahin, Jason; Bielinski, Michael; Guichon, Celine; Flemming, Catherine; Kristof, Arnold S. // Critical Care;2013, Vol. 17 Issue 5, p1 

    Introduction Ventilator-associated respiratory infection (VARI) is an important cause of morbidity in critically-ill patients. Clinical trials performed in heterogeneous populations have suggested there are limited benefits from invasive diagnostic testing to identify patients at risk or to...

  • ACCUMULATION OF ACTIVE PHARMA INGREDIENTS IN POND RARED LABEO ROHITHA. RADHA KRISHNA REDDY, M.; MURALI KRISHNA, A.; REDDY, B.S.; SRILAKSHMI, D.; NARESH KUMAR, Y.; MASTAN, S.A. // International Journal of Pharmacy & Pharmaceutical Sciences;2013, Vol. 5 Issue 2, p519 

    Objective: The present study aimed to estimate the amount of Active Pharma Ingredients in fish tissues of pond rared Labeo rohitha, in and around ponds of Nandivada Mandal, Krishna (Dt), Andrapradesh. Materials and methods: With the aid of Isocratic PEAK HPLC-LC 7000 we understood drastic...

  • Tissue distribution of cloxacillin after intramammary administration in the isolated perfused bovine udder. Kietzmann, Manfred; Niedorf, Frank; Gossellin, Jacques // BMC Veterinary Research;2010, Vol. 6, p46 

    Background: Various intramammary suspensions containing cloxacillin benzathine are registered for use in cattle as antibiotics for intramammary use at drying off. To ensure antibacterial efficacy, the glandular tissue concentration of an antimicrobial agent must be sufficient. Since the...

  • NOVABAY REPORTS POSITIVE PHASE I AGANOCIDE RESULTS FOR MRSA.  // Biotech Business;Jan2008, Vol. 21 Issue 1, p1 

    The article reports on the results of the phase one trials of NovaBay Pharmaceuticals Inc. on the lead Aganocide NVC-422 non-antibiotic anti-infective. The results of the trials show that when topically applied to the anterior nares, NVC-422 appears safe and well tolerated with undetectable...

  • New Fluoroquinolones: A Class of Potent Antibiotics. De Souza, Marcus Vin�cius Nora // Mini Reviews in Medicinal Chemistry;Nov2005, Vol. 5 Issue 11, p1009 

    The discovery of antibiotics opened a new era in the treatment against several pathogenic microorganisms that can disable or kill humans. The appearance of the fluoroquinolones (based on nalidixic acid, 4-quinolone-3-carboxylates), in the early 1980's, gave a new impetus in the treatment of...

  • Tracking the Microbes in Sepsis: Advancements in Treatment Bring Challenges for Microbial Epidemiology. Llewelyn, Martin J.; Cohen, Jonathan // Clinical Infectious Diseases;5/15/2007, Vol. 44 Issue 10, p1343 

    During the 1980s and 1990s, sepsis research propelled dozens of potential therapeutic candidates into clinical trials without a single novel therapeutic approach entering the clinical arena. After the publication of the landmark PROWESS trial in 2001 [1], which showed survival benefit associated...

  • Optimer's Prulifloxacin Data Positive in First Phase III Study. Boggs, Jennifer // BioWorld Today;7/17/2008, Vol. 19 Issue 138, p1 

    The article focuses on Prulifloxacin, the oral broad-spectrum antibiotic of Optimer Pharmaceuticals Inc. which met the primary endpoint in the first of two pivotal trials in infectious diarrhea. Analysis from the Prulifloxacin Phase III study showed that those treated with 600 milligrams of...

  • Rapid Detection of Antibiotic-Resistant Organism Carriage for Infection Prevention. Diekema, Daniel J.; Pfaller, Michael A. // Clinical Infectious Diseases;Jun2013, Vol. 56 Issue 11, p1614 

    Rapid detection of multidrug-resistant organism (MDRO) carriers remains a work in progress. Future efforts should be on developing rapid tests to detect gram-negative MDROs and on performing studies to determine how to incorporate rapid MDRO detection into infection prevention efforts.Rapid...

  • Formulary considerations.  // Formulary;Feb2006, Vol. 41 Issue 2, p73 

    The article focuses on Dalbavancin, a long-acting lipoglycopeptide antibiotic of Pfizer Inc. The antibiotic is currently in phase 3 clinical trials for the treatment of resistant gram-positive pathogens. The mechanism by which the agent exerts its bacterial activity by binding to the terminal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics